InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial

Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced today that the European Commission has granted conditional marketing authorization for LYTGOBI® monotherapy for the treatment of adult patients with locally advanced or metastatic

Amneal Pharmaceuticals, Inc. today announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous

ARUP Laboratories today announced that the U.S. Food and Drug Administration has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox). ROCTAVIAN™, a new gene

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties

TME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment, announces a positive clinical update on the survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12,

Allecra Therapeutics announced today the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth

Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.

Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial.

NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on concentration disorders of the kidney, announces today it has entered an agreement with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family